Biodexa Successfully Appeals Nasdaq Delisting

Oct 16, 2024 (wallstreet-pr.com)- Biodexa Pharmaceuticals (NASDAQ: BDRX) stated that its request for an extension of time to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq Stock Market LLC was approved by a Nasdaq Hearings Panel.

To move forward, Biodexa Pharmaceuticals must remain in compliance with Nasdaq Listing Rule 5550(a)(2), or the "Minimum Bid Price Requirement". The Panel's decision is contingent on the Company maintaining a closing bid price of at least $1.00 per share for at least 20 consecutive trading days by October 31, 2024.

About Wall Street PR

Wall Street PR, a leading press release provider, has proudly served the financial community for over 20 years, providing timely and insightful market news. Our expert team delivers customized press releases that enhance visibility for businesses and investors. With an extensive distribution network and a commitment to accuracy and strategic communications, Wall Street PR ensures that your message reaches the right audience with maximum impact. When Wall Street PR writes about a company, investors pay attention.
[email protected]

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made based on management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

The post Biodexa Successfully Appeals Nasdaq Delisting appeared first on WSTPR.

COMTEX_458858354/2771/2024-10-16T10:23:18

You May Also Be Interested In

• Elektros Inc. Strengthens Its Position in Lithium and EV Innovation as the Global Electrification Era Gains Momentum
• Modat adds Passive DNS to its Platform Magnify, Connecting Every Signal in a Single Investigation Graph
• Modat adds Passive DNS to its Platform Magnify, Connecting Every Signal in a Single Investigation Graph